Please assess the completion status of the following clinical trial:

Trial Title: Switch of Renin-Angiotensin System Inhibitors in Patients With Covid-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hypertension in use of renin-angiotensin system inhibitors~* Confirmed COVID-19 infection by rt-PCR, serology tests or typical clinical presentation and chest CT.~* Symptoms onset \< 96h~* Need for hospitalization~Exclusion Criteria:~* Heart failure~* Previous cerebrovascular disease~* Previous myocardial infarction~* Blood pressure \> 180 x 100 mmHg~* Need for 3 or more anti-hypertensive classes~* Use os spironolactone~* Severe pulmonary disease~* Contraindication for using other anti-hypertensive classes (calcium channel blockers, hydralazine, diuretics or nitrates)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Switch therapy (Type: EXPERIMENTAL): Renin-angiotensin system inhibitors will be changed for other anti-hypertensive classes.
- Maintenance therapy (Type: NO_INTERVENTION): Renin-angiotensin system inhibitors will be kept during in-hospital stay

Based on this trial design, predict the completion outcome and termination type (if applicable).